<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="static/style.xsl"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-06-08T11:05:08Z</responseDate><request verb="GetRecord" identifier="oai:docta.ucm.es:20.500.14352/7131" metadataPrefix="marc">https://docta.ucm.es/rest/oai/request</request><GetRecord><record><header><identifier>oai:docta.ucm.es:20.500.14352/7131</identifier><datestamp>2023-08-26T06:40:44Z</datestamp><setSpec>com_20.500.14352_14</setSpec><setSpec>col_20.500.14352_15</setSpec></header><metadata><record xmlns="http://www.loc.gov/MARC21/slim" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:doc="http://www.lyncode.com/xoai" xsi:schemaLocation="http://www.loc.gov/MARC21/slim http://www.loc.gov/standards/marcxml/schema/MARC21slim.xsd">
   <leader>00925njm 22002777a 4500</leader>
   <datafield ind2=" " ind1=" " tag="042">
      <subfield code="a">dc</subfield>
   </datafield>
   <datafield ind2=" " ind1=" " tag="720">
      <subfield code="a">Galindo Izquierdo, María</subfield>
      <subfield code="e">author</subfield>
   </datafield>
   <datafield ind2=" " ind1=" " tag="720">
      <subfield code="a">Pablos Álvarez, José Luis</subfield>
      <subfield code="e">author</subfield>
   </datafield>
   <datafield ind2=" " ind1=" " tag="260">
      <subfield code="c">2021-01-13</subfield>
   </datafield>
   <datafield ind2=" " ind1=" " tag="520">
      <subfield code="a">The complement system (CS) includes more than 50 proteins and its main function is to recognize and protect against foreign or damaged molecular components. Other homeostatic functions of CS are the elimination of apoptotic debris, neurological development, and the control of adaptive immune responses. Pathological activation plays prominent roles in the pathogenesis of most autoimmune diseases such as systemic lupus erythematosus, antiphospholipid syndrome, rheumatoid arthritis, dermatomyositis, and ANCA-associated vasculitis. In this review, we will review the main rheumatologic autoimmune processes in which complement plays a pathogenic role and its potential relevance as a therapeutic target.</subfield>
   </datafield>
   <datafield ind1="8" ind2=" " tag="024">
      <subfield code="a">2073-4409</subfield>
   </datafield>
   <datafield ind1="8" ind2=" " tag="024">
      <subfield code="a">10.3390/cells10010148</subfield>
   </datafield>
   <datafield ind1="8" ind2=" " tag="024">
      <subfield code="a">https://hdl.handle.net/20.500.14352/7131</subfield>
   </datafield>
   <datafield ind1="8" ind2=" " tag="024">
      <subfield code="a">https://doi.org/10.3390/cells10010148</subfield>
   </datafield>
   <datafield ind1="8" ind2=" " tag="024">
      <subfield code="a">https://www.mdpi.com/2073-4409/10/1/148/htm</subfield>
   </datafield>
   <datafield ind2="0" ind1="0" tag="245">
      <subfield code="a">Complement as a Therapeutic Target in Systemic Autoimmune Diseases</subfield>
   </datafield>
</record></metadata></record></GetRecord></OAI-PMH>